Breast Biopsy, Local Excision DRG 584

DRG 584 covers inpatient breast biopsy, local excision, and related breast procedures when a Complication or Comorbidity or a Major Complication or Comorbidity is present. Correct classification affects Medicare inpatient reimbursement because severity-adjusted Diagnosis-Related Group assignment drives payment levels for these surgical admissions.

DRG 584 Overview

DRG 584 covers inpatient stays for breast biopsy, local excision, and other breast procedures when a Complication or Comorbidity or a Major Complication or Comorbidity is present. It includes surgical management of suspicious or confirmed breast lesions requiring more than outpatient-level care, and cases where comorbid conditions affect resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity affects reimbursement relative to lower-severity groups for similar procedures. Accurate clinical coding of procedures and comorbid conditions determines assignment to this Diagnosis-Related Group and the associated inpatient payment rate.

Trials comparing minimally invasive biopsy techniques versus open local excision for suspicious breast lesions focus on diagnostic accuracy, complication rates, and short-term surgical outcomes. These studies enroll patients presenting with imaging-detected or palpable breast lesions referred for tissue diagnosis, often stratified by lesion size and location. Results inform provider choice of diagnostic pathway, influence inpatient length of stay and complication-related costs, and help payers evaluate the value of less invasive approaches for patients classified under this DRG.
Comparative effectiveness studies of perioperative management strategies (e.g., anesthesia modality, drain use, and antimicrobial prophylaxis protocols) examine postoperative pain, wound complication rates, and readmissions after breast biopsy or excisional procedures. These trials typically include adults undergoing local excision or other breast procedures, including those with comorbid conditions that increase complication risk (CC/MCC). Findings guide clinical pathways to reduce complications and unplanned returns, directly impacting resource utilization and reimbursement profiles for hospitals treating these patients.
Prospective registry-based and outcomes research following patients after breast-conserving biopsies and excisions assess long-term cosmetic outcomes, need for re-excision, and subsequent cancer diagnosis rates. These studies follow diverse outpatient and inpatient cohorts over months to years to capture downstream diagnostic or therapeutic interventions and patient-reported outcomes. Data are valuable to providers and payers because they quantify downstream costs and quality-of-care metrics associated with initial procedural choices under this DRG, informing bundle payment design and quality improvement efforts.

Trials comparing minimally invasive biopsy techniques versus open local excision for suspicious breast lesions focus on diagnostic accuracy, complication rates, and short-term surgical outcomes. These studies enroll patients presenting with imaging-detected or palpable breast lesions referred for tissue diagnosis, often stratified by lesion size and location. Results inform provider choice of diagnostic pathway, influence inpatient length of stay and complication-related costs, and help payers evaluate the value of less invasive approaches for patients classified under this DRG.
Comparative effectiveness studies of perioperative management strategies (e.g., anesthesia modality, drain use, and antimicrobial prophylaxis protocols) examine postoperative pain, wound complication rates, and readmissions after breast biopsy or excisional procedures. These trials typically include adults undergoing local excision or other breast procedures, including those with comorbid conditions that increase complication risk (CC/MCC). Findings guide clinical pathways to reduce complications and unplanned returns, directly impacting resource utilization and reimbursement profiles for hospitals treating these patients.
Prospective registry-based and outcomes research following patients after breast-conserving biopsies and excisions assess long-term cosmetic outcomes, need for re-excision, and subsequent cancer diagnosis rates. These studies follow diverse outpatient and inpatient cohorts over months to years to capture downstream diagnostic or therapeutic interventions and patient-reported outcomes. Data are valuable to providers and payers because they quantify downstream costs and quality-of-care metrics associated with initial procedural choices under this DRG, informing bundle payment design and quality improvement efforts.

OpenPayer

Summary & Overview

Breast Biopsy, Local Excision and Other Breast Procedures with CC/MCC: Inpatient Reimbursement Overview

DRG 584 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes